Physical Activity in Pregnancy (PAP)
Effect of Physical Activity in Pregnancy on Low Grade Inflammation: a Pilot Study
調査の概要
状態
条件
詳細な説明
Pregnancy is a natural state of low grade inflammation in the mother and the feto-placental unit. The severity of this inflammation increases with higher pregravid Body Mass Index (BMI). This is reflected by an increase in pro-inflammatory cytokines in the maternal circulation and in the placenta. It has been proposed that the pro-inflammatory maternal and fetal environment plays a role in mediating pregnancy outcomes.
In non-pregnant individuals regular physical activity is associated with a reduced inflammatory state. The overall objective of the study is to investigate the interaction of maternal physical activity and pregnancy induced low-grade inflammation in the mother and feto-placental unit, and to assess th resulting effects on prenatal and postnatal development.
Specific research objective will be to study effects of maternal physical activity on:
- low grade Inflammation in the mother an feto-placental unit;
- maternal and fetal lipid profiles, including High Density Lipoprotein (HDL) proteome;
- fetal growth and infant body composition;
- transcriptomic and epigenetic profile in the placenta;
- biomarkers of nutritive status;
- psychological assessment: cardiac awareness; assessment of arterial stiffness; stress-coping questionaire
研究の種類
入学 (実際)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- ongoing pregnancy no later than 14 weeks of gestation
- giving informed consent
Exclusion Criteria:
- not wanting to give birth at the University Hospital
- gestational age > 14 weeks of gestation
- 3 or more consecutive miscarriages
- increased risk to or above 1:200 after combined test (Minimum parameters: maternal age, fetal crown-rump length (CRL), nuchal translucency, nasal bone and maternal biochemistry)
- fetal anomalies associated with possible growth or genetic anomalies
- Smoking
- diagnosed with Diabetes type 1 or 2 (T1D, T2D)
- for groups 1 and 2: maternal metabolic risk factors (autoimmune conditions, increased risk for thromboembolic events needing anticoagulative therapy)
- for groups 1 and 2: pre-pregnancy hypertension
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Active
pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
|
Inactive
pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
|
risk for hypertensive disorders
pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
low grade inflammation (in maternal and cord blood)
時間枠:1 year
|
clinical inflammation markers: C-reactive protein, cytokines and chemokine (IL1b, IL1a, IL-2, IL-5, IL-6,IL-12, TNFa, MCP-1, MIP1-a) measured by ELISA and multiplexing arrays
|
1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
maternal and fetal (cord blood) lipid profiles
時間枠:1 year
|
triglycerides, phospholipids, free fatty acids, HDL/LDL/total cholesterol
|
1 year
|
neonatal body composition (% body fat)
時間枠:1 year
|
measured by air displacement plethysmography (Peapod)
|
1 year
|
maternal and newborn fat distribution
時間枠:1 year
|
subcutaneous adipose tissue thickness at 15 defined body sites, measured by a lipometer
|
1 year
|
fetal growth
時間枠:1 year
|
measured by ultrasound scanner
|
1 year
|
transcriptome of the placenta
時間枠:2 years
|
measured by full genome arrays
|
2 years
|
epigenetic analysis of the placenta
時間枠:2 years
|
analysed by 450k methylation arrays
|
2 years
|
biomarkers of nutritional status
時間枠:2 years
|
measurement of blood levels of fatty acids (DHA, EPA, 15:0, 17:0), vitamin A, B1, B2, B6, D2/D3, C, E, homocysteine
|
2 years
|
psychological assessment
時間枠:1 year
|
assessment of arterial stiffness, stress coping questionnaire, cardiac awareness
|
1 year
|
協力者と研究者
捜査官
- 主任研究者:Bence Csapo, MD、Medical University of Graz
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- EK 24-245 ex 11/12
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。